Zoledronic acid as an antimetastatic agent for different human tumor cell lines

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5295-5300

  Muinelo Romay, Laura ^a   Garcia, Daniel ^a   Alonso Alconada, Lorena ^a   Vieito, María ^a   Carmona, Marta ^a   Martínez, Nieves ^a   Aguín, Santiago ^a   Abal, Miguel ^a   López López, Rafael ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

3D culture assays; Invasion; Metastasis; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ARTICLE; ASSAY; BREAST CANCER; CANCER CELL CULTURE; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; METASTASIS INHIBITION; OVARY CANCER; PRIORITY JOURNAL; TUMOR INVASION;

EID: 84891475920     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mystakidou K, Katsouda E, Stathopoulou E and Vlahos L: Approaches to managing bone metastases from breast cancer: the role of bisphosphonates. Cancer Treat Rev 31: 303-311, 2005.
2. Russell RG and Rogers MJ: Bisphosphonates: From the laboratory to the clinic and back again. Bone 25: 97-106, 1999.
3. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M and Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88: 1082-1090, 2000.
4. Buhaescu I and Izzedine H: Mevalonate pathway: A review of clinical and therapeutical implications. Clin Biochem 40: 575-584, 2007.
5. Monkkonen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsalainen J and Monkkonen J: A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 147: 437-445, 2006.
6. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363, 1998.
7. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R and Marth C: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691, 2009.
8. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J and Weilbaecher K: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase II trial. Lancet Oncol 11: 421-428, 2009.
9. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ and Thorpe H: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct antitumour activity in breast cancer. Br J Cancer 102: 1099-1105, 2010.
10. Yuasa T, Kimura S, Ashihara E, Habuchi T and Maekawa T: Zoledronic acid - a multiplicity of anticancer action. Curr Med Chem 14: 2126-35, 2007.
11. Senaratne SG and Colston KW: Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4: 18-23, 2002.
12. Dumon JC, Journe F, Kheddoumi N, Lagneaux L and Body JJ: Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 45: 521-528; discussion 528-529, 2004.
13. Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF and Scheper MA: Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog 10: 2, 2011.
14. Li XY, Lin YC, Huang WL, Hong CQ, Chen JY, You YJ and Li WB: Zoledronic acid inhibits proliferation and impairs migration and invasion through down-regulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells. Med Oncol 29: 714-720, 2011.
15. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061, 2002.
16. Denoyelle C, Hong L, Vannier JP, Soria J and Soria C: New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 88: 1631-1640, 2003.
17. Muinelo-Romay L, Colas E, Barbazan J, Alonso-Alconada L, Alonso-Nocelo M, Bouso M, Curiel T, Cueva J, Anido U, Forteza J, Gil-Moreno A, Reventos J, Lopez-Lopez R and Abal M: High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion. Mol Cancer Ther 10: 1357-1366, 2011.
18. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593, 2002.
19. Bosch-Barrera J, Merajver SD, Menendez JA and Van Poznak C: Direct antitumour activity of zoledronic acid: Preclinical and clinical data. Clin Transl Oncol 13: 148-55, 2011.
20. Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell 147: 275-292, 2011.
21. Oxford G and Theodorescu D: RAS superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 189: 117-128, 2003.
22. Montague R, Hart CA, George NJ, Ramani VA, Brown MD and Clarke NW: Differential inhibition of invasion and proliferation by bisphosphonates: Antimetastatic potential of zoledronic acid in prostate cancer. Eur Urol 46: 389-401; discussion 401-402, 2004.
23. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM and Clezardin P: Bis phosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000.
24. Sewing L, Steinberg F, Schmidt H and Goke R: The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13: 782-789, 2008.
25. Nishida S, Fujii Y, Yoshioka S, Kikuichi S, Tsubaki M, and Irimajiri K: A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci 73: 2655-2664, 2003.
26. Kuroda J, Kimura S, Segawa H, Sato K, Matsumoto S, Nogawa M, Yuasa T, Kobayashi Y, Yoshikawa T, Ottmann OG and Maekawa T: p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci 95: 186-192, 2004.
27. Merrell M, Suarez-Cuervo C, Harris KW, Vaananen HK and Selander KS: Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Res Treat 81: 231-241, 2003.
28. Fromigue O, Lagneaux L and Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211-2221, 2000.